Clinical Trials Browser

Terminated × INDUSTRY × enzalutamide × Clear all

NCT03437941 2026-05-15

Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Terminated

39 enrolled 43 charts

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT05588609 2026-04-27

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Phase 2 Terminated

GenitourinaryThoracic

NSCLC Harboring NRG1 Fusion

NCT04179864 2026-03-10

CELLO-1

Phase 1/2 Terminated

102 enrolled 39 charts

Prostatic Neoplasms

NCT05551117 2026-02-09

Tamarack

Phase 2 Terminated

192 enrolled 20 charts

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Carcinoma, Small Cell, Small Cell Lung Carcinoma, Prostatic Neoplasms, Castration-Resistant

NCT05252390 2025-11-06

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Phase 1 Terminated

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Triple Negative Breast Neoplasms

NCT04631601 2025-10-07

Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)

Phase 1/2 Terminated

Bites and Stings

NCT05075577 2025-02-28

EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC

Phase 1/2 Terminated

Prostatic Neoplasms

NCT03850795 2024-08-19

HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Phase 3 Terminated

Prostate Cancer Metastatic

NCT03685591 2024-06-26

PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors

Phase 1 Terminated

49 enrolled 33 charts

BreastDermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Adenocarcinoma, Breast Neoplasms, Carcinoma, Renal Cell, Camurati-Engelmann Syndrome, Liver Neoplasms, Melanoma, Mesothelioma, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Neoplasms, Squamous Cell

NCT04844749 2024-02-05

VERACITY

Phase 3 Terminated

Prostatic Neoplasms, Castration-Resistant

NCT04033328 2023-12-15

Study of ORIC-101 in Combination With Enzalutamide

Phase 1 Terminated

Prostatic Neoplasms

NCT04157088 2023-08-04

DaroAcT

Phase 2 Terminated

30 enrolled 25 charts

Prostatic Neoplasms, Castration-Resistant

NCT02438007 2023-03-15

ARMOR3-SV

Phase 3 Terminated

Prostatic Neoplasms

NCT03150056 2022-08-10

Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer

Phase 1 Terminated

73 enrolled 34 charts

Other solid neoplasm

Solid Tumours

NCT04052204 2021-10-14

Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors

Phase 1/2 Terminated

3 enrolled 12 charts

Squamous Cell Carcinoma of Head and Neck

NCT02607228 2020-12-08

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer

Phase 1/2 Terminated

31 enrolled 22 charts

Metastatic Castrate-Resistant Prostate Cancer

NCT02379390 2019-06-21

PRIMCAB

Phase 2 Terminated

8 enrolled 8 charts

Prostate Cancer Metastatic

NCT02441517 2018-04-19

A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment

Phase 4 Terminated

4 enrolled 12 charts

Neoplasm Metastasis, Prostatic Neoplasms